Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

272.96 0.64 +0.24%
Market cap
$655.6B
P/E
41.3×
Fwd P/E
40.0×
Dividend yield
1.94%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Total current assets
56,351.00 59,774.00 59,173.00 55,624.00
Total non-current assets
141,074.00 141,287.00 141,721.00 143,586.00
Total Assets
197,425.00 201,061.00 200,894.00 199,210.00
Total current liabilities
55,457.00 54,895.00 57,716.00 54,126.00
Total non-current liabilities
60,439.00 61,195.00 61,992.00 63,540.00
Total liabilities
115,896.00 116,090.00 119,708.00 117,666.00
Common Equity (Total)
81,529.00 84,971.00 81,186.00 81,544.00
Shareholders Equity (Total)
81,529.00 84,971.00 81,186.00 81,544.00
Total Debt
35,799.00 37,344.00 37,527.00 39,438.00

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 2 Nov 2026